Dermatology

Delphine Kerob, MD, in this segment of her interview, expanded on the clinical implications of new data on atopic dermatitis and lifelong impacts.

A study revealed adults with childhood onset atopic dermatitis may see greater limitations in career and educational options.

Jonathan Bernstein, MD, discusses remibrutinib, c-kit inhibitors, and the current limits of biomarker-guided decision-making in chronic spontaneous urticaria.

The latest ABCs of Dermatology explored the future potential of amlitelimab in atopic dermatitis and the potential of OX40 ligand-targeted therapy.

This interview highlights key facts regarding HS in honor of Hidradenitis Suppurativa (HS) Awareness Week, featuring Kiera Booth, MD.

This segment of the Skin of Color Savvy podcast highlights how dermatologists can improve sunscreen adherence among individuals with skin of color.

Bernstein discussed the evolving role of biomarkers in chronic spontaneous urticaria at EAC 2026.

This interview highlights topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with atopic dermatitis.

This segment of the May episode of The Medical Sisterhood highlights the importance of addressing patients' and parents' fears in dermatology.

Amlitelimab was discussed in the ABCs in Dermatology podcast, with the hosts highlighting atopic dermatitis patient demographics and high disease burden.

In a recent episode of The Medical Sisterhood podcast, Lisa Swanson, MD, spoke about the importance of female mentorship in medicine.

This segment of the latest Skin of Color Savvy podcast highlighted persistent disparities in skin cancer prevention, awareness, and diagnosis.

Explore OX40/OX40L inhibition in atopic dermatitis: phase 3 amlitelimab efficacy, safety signals, and what upstream immune control could mean.

These topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with moderate-to-severe atopic dermatitis.

This episode highlights the importance of closing persistent gaps in skin cancer prevention and awareness for patients with skin of color.

This Q&A interview highlights the broader implications of the phase 3b TOGETHER-PsO trial for ixekizumab and tirzepatide in managing psoriatic disease.

This interview highlights recent phase 3b data from the TOGETHER-PsO trial on ixekizumab and tirzepatide for psoriasis and obesity or overweight.

This segment of a Q&A interview with Kilian Eyerich, MD, PhD, highlights the signficance of the LumiNE phase 3 study on lebrikizumab.

A new phase 3 study is evaluating lebrikizumab in at least 270 patients with nummular eczema over 48 weeks.

As dermatology patients enter clinical visits with information from social media, online forums, and AI inquiries, clinicians are juggling new concerns.

Phase 2 LANTIC trial data show corabotase maintained glabellar line improvement in 60.8% of patients at week 24 versus 36.7% for Dysport.

Adults with difficult-to-treat psoriasis due to overweight or obesity saw notable benefits to both with concomitant ixekizumab and tirzepatide.

Patients with atopic dermatitis and prurigo nodules (AD-PN) saw notable itch reduction in 12 weeks after initiating upadacitinib.

In this May episode of The Medical Sisterhood podcast, the show features guest Lisa Swanson, MD, discussing the emotional realities of pediatric dermatology.

Treatment-associated phenotype switching between psoriasis and atopic dermatitis was noted to be reproducible and bidirectional in real-world clinical settings.